CYTOKINETICS INC false 0001061983 0001061983 2024-06-07 2024-06-07

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): June 7, 2024

 

 

Cytokinetics, Incorporated

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   000-50633   94-3291317
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification Number)

350 Oyster Point Boulevard, South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 624-3000

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001   CYTK   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


ITEM 8.01

Other Events.

Exercise of Option to Purchase Additional Shares

On June 7, 2024, pursuant to an underwriting agreement (the “Underwriting Agreement”) by and among Cytokinetics, Incorporated (the “Company”) and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC (collectively, the “Underwriters”) dated May 22, 2024, relating to the public offering, issuance and sale of 9,803,922 shares of the Company’s common stock (“Common Stock”), the Underwriters purchased an additional 1,470,588 shares of Common Stock pursuant to the exercise in full of the Underwriters’ option to purchase additional shares. The gross proceeds to the Company from the sale of the additional shares were approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CYTOKINETICS, INCORPORATED
Date: June 7, 2024     By:  

/s/ Sung Lee

      Sung Lee
      Executive Vice President, Chief Financial Officer
v3.24.1.1.u2
Document and Entity Information
Jun. 07, 2024
Cover [Abstract]  
Entity Registrant Name CYTOKINETICS INC
Amendment Flag false
Entity Central Index Key 0001061983
Document Type 8-K
Document Period End Date Jun. 07, 2024
Entity Incorporation State Country Code DE
Entity File Number 000-50633
Entity Tax Identification Number 94-3291317
Entity Address, Address Line One 350 Oyster Point Boulevard
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 624-3000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001
Trading Symbol CYTK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

Grafico Azioni Cytokinetics (NASDAQ:CYTK)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Cytokinetics
Grafico Azioni Cytokinetics (NASDAQ:CYTK)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Cytokinetics